Biden’s prescription drugs cap will save seniors over $1,000 yearly starting in 2025, study finds

More than 1 million people in the U.S. will save over $1,000 a year beginning in 2025, when an annual $2,000 cap on prescription drug out-of-pocket costs kicks in, the leading lobbying group for older Americans said on Wednesday.

The cap, introduced as part of President Joe Biden’s Inflation Reduction Act, applies to the Medicare program for people age 65 or over and those with disabilities. Its prescription drug component, known as Part D, provides coverage for around 56 million people.

AARP, which lobbied in favor of the law, commissioned health consultancy Avalere to conduct a study on the new benefit and published a report on the findings on Wednesday.

The $2,000 cap will lower prices in 2025 for more than 3.2 million people, or around 8.4% of Part D beneficiaries who do not receive other subsidies, AARP said in its report.

That represents a stark change from how Medicare Part D previously worked. Before the Inflation Reduction Act, beneficiaries who did not qualify for low income subsidies were required to pay 5% of drug costs regardless of how much they had already paid.

By 2029, the lowered cap will help 4.1 million, or around 9.6% of beneficiaries, AARP said.

The biggest impact will be felt by those who use high-priced, branded drugs the most.

Almost 40% of people who reach the cap over those five years, some 1.4 million, will save more than $1,000 a year, including 420,000 people, or around 12%, who will save more than $3,000 annually. Currently, some patients pay over $10,000 a year, AARP said in its report.

The study excluded Part D beneficiaries who receive low income subsidies and pay nominal amounts for drugs from its analysis.

“The money seniors will no longer have to spend out-of-pocket is money they can invest in their families, broader health needs or simply save to achieve greater financial stability,” AARP CEO Jo Ann Jenkins said.

—Ahmed Aboulenein, Reuters